Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.

被引：0
|
作者：
Ravandi, Farhad
Carraway, Hetty E.
Taningco, Lilia
Laille, Eric
Gong, Jing
Prebet, Thomas
De Menezes, Daniel Lopes
Wei, Andrew H.
机构：
[1] Univ Texas MD derson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Taussig Canc Inst, Cleveland Clin, Leukemia Program, Cleveland, OH USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Peter MacCallum Canc Ctr, Melbourne, VIC, Australia
[5] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7068
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Walker, Alison R.
    Vasu, Sumithra
    Mims, Alice S.
    Walsh, Katherine J.
    Behbehani, Gregory K.
    Blachly, James S.
    Vittorio, Molly
    Zhao, Qiuhong
    Ruppert, Amy S.
    Orwick, Shelley
    Ranganathan, Parvathi
    Byrd, John C.
    Blum, William
    Garzon, Ramiro
    BLOOD, 2016, 128 (22)
  • [22] A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
    Zeidan, Amer M.
    Borate, Uma
    Pollyea, Daniel A.
    Brunner, Andrew M.
    Roncolato, Fernando
    Garcia, Jacqueline S.
    Filshie, Robin
    Odenike, Olatoyosi
    Watson, Anne Marie
    Krishnadasan, Ravitharan
    Bajel, Ashish
    Naqvi, Kiran
    Zha, Jiuhong
    Cheng, Wei-Han
    Zhou, Ying
    Hoffman, David
    Harb, Jason G.
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (02) : 272 - 281
  • [23] Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Cherry, Evan M.
    Abbott, Diana
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Rosser, Julie
    Sato, Audrey
    Schowinsky, Jeffrey
    Inguva, Anagha
    Minhajuddin, Mohd
    Pei, Shanshan
    Stevens, Brett
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2021, 5 (24) : 5565 - 5573
  • [24] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kim, Kunhwa
    Kantarjian, Hagop
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas J.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Chien, Kelly S.
    Daver, Naval
    Pemmaraju, Naveen
    Jain, Nitin
    Adewale, Lade
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Verstovsek, Srdan
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [25] Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Przespolewski, Amanda
    Griffiths, Elizabeth A.
    Thompson, James E.
    Elshoury, Amro
    Emadi, Ashkan
    Duong, Vu H.
    Niyongere, Sandrine
    Walinski, Wendy
    Said, Meriem
    Halliwell, Stephanie
    Eke, Kemji
    Attwood, Kristopher
    Baer, Maria R.
    Wang, Eunice S.
    BLOOD, 2020, 136
  • [26] Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
    Fleming, Shaun
    Roboz, Gail J.
    Fathi, Amir T.
    Zhang, Tian Y.
    Wei, Andrew
    Carraway, Hetty E.
    Holes, Leanne
    Petrlik, Erica
    Prebet, Thomas
    Menezes, Daniel L.
    Bluemmert, Iryna
    Sun, Hao
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S293 - S293
  • [27] Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study
    Pratz, Keith W.
    DiNardo, Courtney D.
    Selleslag, Dominik
    Li, Junmin
    Yamamoto, Kazuhito
    Konopleva, Marina
    McDonald, Andrew
    Babu, Sunil
    Stevens, Don A.
    Kantarjian, Hagop M.
    Traina, Fabiola
    Venditti, Adriano
    Mayer, Jiri
    Montez, Melissa
    Ramsingh, Giridharan
    Jin, Huan
    Ainsworth, William
    Duan, Yinghui
    Svensson, Anders Erik
    Werner, Michael
    Potluri, Jalaja
    Jonas, Brian A.
    BLOOD, 2020, 136
  • [28] Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
    Konopleva, Marina Y.
    Dail, Monique
    Daver, Naval G.
    Garcia, Jacqueline S.
    Jonas, Brian A.
    Yee, Karen W. L.
    Kelly, Kevin R.
    Vey, Norbert
    Assouline, Sarit
    Roboz, Gail J.
    Paolini, Stefania
    Pollyea, Daniel A.
    Tafuri, Agostino
    Brandwein, Joseph M.
    Pigneux, Arnaud
    Powell, Bayard L.
    Fenaux, Pierre
    Olin, Rebecca L.
    Visani, Giuseppe
    Martinelli, Giovanni
    Onishi, Maika
    Wang, Jue
    Huang, Weize
    Dunshee, Diana R.
    Hamidi, Habib
    Ott, Marion G.
    Hong, Wan-Jen
    Andreeff, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 364 - 374
  • [29] Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia
    Chen, Nianci
    Zhou, Yile
    Tong, Hongyan
    Wei, Juying
    Lou, YinJun
    Zhou, De
    Fan, Cuihua
    Huang, Li
    Mao, Liping
    Li, Chenying
    Wang, Huafeng
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
    Saxena, Kapil
    Herbrich, Shelley M.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Pierce, Sherry A.
    Jabbour, Elias
    Wang, Sa A.
    Bueso-Ramos, Carlos
    Loghavi, Sanam
    Tang, Guillin
    Cheung, Cora M.
    Alexander, Lynette
    Kornblau, Steven
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Konopleva, Marina Y.
    Daver, Naval
    CANCER, 2021, 127 (20) : 3761 - 3771
12345